CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Blincyto for MRD-positive B-cell precursor ALL — Details

Project Number PC0204-000
Brand Name Blincyto
Generic Name Blinatumomab
Strength 38.5 mcg
Tumour Type Leukemia
Indication Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL)
Funding Request Patients with Philadelphia chromosome-negative CD19 positive B-precursor acute lymphoblastic leukemia (ALL) in first or second hematologic complete remission with minimal residual disease (MRD) greater than or equal to 0.1%
Review Status Complete
Pre Noc Submission No
NOC Date December 19, 2019
Manufacturer Amgen Canada Inc
Sponsor Amgen Canada Inc
Submission Date January 20, 2020
Submission Deemed Complete February 3, 2020
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ February 3, 2020
Check-point meeting April 9, 2020
pERC Meeting August 20, 2020
Initial Recommendation Issued September 3, 2020
Feedback Deadline ‡ September 18, 2020
pERC Reconsideration Meeting October 15, 2020
Final Recommendation Issued October 29, 2020
Notification to Implement Issued November 13, 2020
Therapeutic Area MRD+ ALL Resubmission
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.